POSTOPERATIVE IRRADIATION FOR SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY: 35-YEAR EXPERIENCE

Size: px
Start display at page:

Download "POSTOPERATIVE IRRADIATION FOR SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY: 35-YEAR EXPERIENCE"

Transcription

1 POSTOPERATIVE IRRADIATION FOR SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY: 35-YEAR EXPERIENCE Russell W. Hinerman, MD, 1 William M. Mendenhall, MD, 1 Christopher G. Morris, MS, 1 Robert J. Amdur, MD, 1 John W. Werning, MD, 2 Douglas B. Villaret, MD 2 1 Department of Radiation Oncology, University of Florida Shands Cancer Center, PO Box , Gainesville, FL hinerrw@shands.ufl.edu 2 Department of Otolaryngology, University of Florida, Gainesville, Florida Accepted 19 April 2004 Published online 30 September 2004 in Wiley InterScience ( DOI: /hed Abstract: Background. The purpose of this study was to analyze factors influencing outcome in patients who received postoperative irradiation for advanced squamous cell carcinoma of the oral cavity. Methods. Between October 1964 and November 2000, 226 patients with 230 previously untreated primary invasive squamous cell carcinomas of the oral cavity were treated postoperatively with continuous-course external beam irradiation. All patients had a minimum follow-up of 2 years (analysis, November 2002). No patient was lost to follow-up. Results. The 5-year actuarial rates of locoregional control by pathologic American Joint Committee on Cancer stage were: stage I, 100%; stage II, 84%; stage III, 78%; and stage IV, 66%. Recurrence of cancer above the clavicles developed in 55 patients (24%). In multivariate analysis of locoregional control, positive margins, vascular invasion, perineural invasion, extracapsular extension, and T classification remained significant. Conclusions. This article provides additional data defining relatively favorable and unfavorable groups of patients in the postoperative setting. Dose recommendations are re-examined and selectively increased for high-risk patients. A 2004 Wiley Periodicals, Inc. Head Neck 26: , 2004 Correspondence to: R. W. Hinerman Presented at the 88th Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL, Dec 1 6, Reprints are not available from the authors. B 2004 Wiley Periodicals, Inc. Keywords: carcinoma; squamous cell; mouth; radiotherapy; mouth neoplasms; postoperative care The rationale for postoperative radiotherapy (RT) is that it is most likely to be effective against microscopic deposits of cancer cells, which would progress and lead to locoregional recurrence if left unchecked. 1 In 1989, our results were published on 134 patients who underwent postoperative irradiation for tumors of oral, pharyngeal, or laryngeal sites at the University of Florida. Included were 38 patients with oral cavity cancers. During the period covered in our initial review, the institutional policy was to use primary irradiation for most oral cavity cancers. In the early 1980s, the approach to oral cavity cancer changed at the University of Florida such that almost all patients were treated initially by operation with postoperative irradiation added as indicated by pathologic findings. The main reason for the change was to avoid the relatively high incidence of bone exposure and soft tissue necrosis observed in patients treated predominantly for oral tongue and floor of mouth cancers with interstitial irradiation. This series updates 984 Postoperative Radiotherapy for Squamous Cell Carcinoma

2 Table 1. Patient population (n = 226). Parameter No. patients (%) Sex Male 167 (74) Female 59 (26) Primary site Retromolar trigone 53 (23) Alveolar ridge 27 (12) Floor of mouth 71 (31) Oral tongue 58 (25) Buccal mucosa 4 (2) Gingivobuccal sulcus 9 (4) Hard palate 4 (2) Neck dissection Unilateral 154 (68) Bilateral 57 (25) None 15 (7) Clinical N status N0 124 (55) N1 47 (21) N2 N3 55 (24) Pathologic N status N0 99 (44) N1 42 (19) N2 N3 85 (38) Clinical T classification T1 21 (9) T2 78 (35) T3 48 (21) T4 79 (35) Pathologic T classification T1 18 (8) T2 75 (33) T3 44 (19) T4 89 (39) No. of pathologically positive nodes No neck dissection 15 (7) 0 86 (38) 1 44 (19) (19) z 4 37 (16) Margin status Positive 68 (30) Negative 83 (37) Close/equivocal 75 (33) Extracapsular extension (ECE) ECE+ 43 (19) ECE 42 (19) No data 141 (62) Perineural invasion (PNI) PNI+ 83 (37) PNI 40 (18) No data 103 (46) Clinical AJCC stage I 16 (7) II 47 (21) III 51 (23) IVA 110 (49) IVB 2 (1) Pathologic AJCC stage I 9 (4) II 35 (15) III 39 (17) Table 1. (continued). Parameter No. patients (%) IVA 142 (63) IVB 1 (1) No. of risk factors per patient 0 12 (5) 1 60 (27) 2 52 (23) 3 53 (23) 4 30 (13) 5 14 (6) 6 or 7 5 (2) Dose received (Gy) V (21) > (28) > (25) our experience to include 226 patients with oral cavity malignancies. METHODS AND MATERIALS Between October 1964 and November 2000, 226 patients with 230 previously untreated primary invasive squamous cell carcinomas of the oral cavity (excluding the lip) were treated postoperatively with continuous-course external beam irradiation in the University of Florida Department of Radiation Oncology. All living patients had a minimum follow-up of 2 years (analysis, November 2002). No patient was lost to follow-up. The mean and median follow-up times were 4.8 and 3.2 years, respectively. Patients ranged from 15 to 85 years of age (mean, 60; median, 61). There were 167 men and 59 women. Disease was staged according to the guidelines of the 1997 American Joint Committee on Cancer (AJCC) 2 (Table 1). Stages IVA and IVB were grouped together for statistical analyses, because only two patients were initially seen with clinical stage IVB disease. Four patients had two synchronous oral cavity cancers. In each of these cases, only one TNM stage was assigned, corresponding to the most advanced lesion. Statistical analysis was done for 226 patients rather than 230 separate tumors. All patients underwent a major cancer operation (eg, partial glossectomy, maxillectomy, tongue-jaw-neck dissection) with or without neck dissection before irradiation. Patients referred for irradiation after excisional biopsy of early cancers were excluded. Most patients were treated in the 1980s and 1990s. Before that time, most early and moderately advanced oral cancers received pri- Postoperative Radiotherapy for Squamous Cell Carcinoma 985

3 mary irradiation. Irradiation was started as soon as feasible after surgery, usually within 4 to 6 weeks. No patient received chemotherapy except for palliation after tumor recurrence. Indications for postoperative RT are listed in Table 2. Twelve patients had none of our usual indications for postoperative irradiation but were irradiated because the surgeon believed the patient was at high risk of local recurrence. Margins of resection at the primary site were negative in 83 patients (37%), positive in 68 patients (30%), and close/equivocal in 75 patients (33%) (close [invasive or carcinoma in situ {CIS} V5 mm] in 41 [18%], initially positive but ultimately negative in 26 [12%], contained CIS or dysplasia in seven [3%], and uncertain in one [0.4%]). The latter grouping into the close/equivocal category was done because of the small number of patients in each category and because no significant difference was seen in local or locoregional control rates between the different subgroups. All patients were treated with megavoltage photon beams, usually 60 Co or 6 MV. The mean doses according to margin status in 218 patients who were treated by external irradiation alone (eight additional patients received an interstitial implant) were as follows: negative margins, 64.8 Gy; positive margins, 72 Gy; and close/ equivocal, 66 Gy. No patient in this series was treated with intensity-modulated radiation therapy (IMRT). All patients were treated with planned continuous-course external beam RT. Sixty-nine patients received twice-a-day irradiation at 1.2 Gy per fraction to a median dose of 74.4 Gy (range, 64 Gy 76.8 Gy). One hundred forty-nine patients were treated once daily to a median dose of 65 Gy (range, 21.6 Gy 70.5 Gy). Eight additional patients received an interstitial implant after external beam irradiation. The posterior cervical and low-neck regions (unilateral or bilateral) were irradiated in most patients. All scars, needle tracks, and drain sites Table 2. Indications for postoperative radiation.. T4 (Bone invasion/soft tissue of neck). Multiple positive nodes. Extracapsular spread. Perineural invasion. Vascular invasion. Margins, close (V 5 mm), positive, CIS/dysplasia, or initially positive but negative after re-excision Abbreviation: CIS, carcinoma in situ. were bolused during irradiation with 0.5-cm thick petrolatum gauze. Statistical Methods. All statistical analyses were performed with SAS software (SAS Institute, Cary, NC). 3 Univariate survival estimates were obtained by the Kaplan-Meier method. 4 The logrank statistic was used to detect differences between strata, and corresponding two-sided p values of less than.05 were interpreted as statistically significant. Cox regression was implemented for multivariate analyses. 5 Specifically, backward selection was performed to attain the most parsimonious model for each endpoint of interest. Multiple imputation was implemented to allow the most unbiased estimates in the presence of explanatory variables with randomly missing information. Those patients not receiving a neck dissection were excluded from multivariate analyses. The presence of severe complications was analyzed with logistic regression; those patients receiving an implant rather than external beam RT were excluded, because hyperfractionation was one of the covariates in this analysis. RESULTS Local (Primary) Control. The 5-year actuarial rate of primary site control was 83%. There was no significant difference ( p =.16) in the 5-year local control rates according to tumor location within the oral cavity: oral tongue, 84%; retromolar trigone, 76%; floor of mouth, 85%; and other, 70%. There was a significant difference in local control according to margin status ( p =.0004): positive, 63% (n = 68); negative, 82%; and close/ equivocal, 92%. The difference in local control rates according to preoperative clinical T classification was also significant ( p =.04): T1, 90%; T2, 88%; T3, 79%; and T4, 70%. Local control rates did not correlate with clinical N status or with the number of lymph nodes involved in the pathologic neck dissection specimen. Five-year local control rates according to clinical N status were as follows ( p =.96): N0, 79%; N1, 78%; and N2 N3, 84%. Local control according to the number of pathologically positive lymph nodes were as follows: none, 81%; one, 82%; two to three, 86%; four or more, 78% ( p =.73). Regional (Neck) Control. The 5-year rates of neck control by the number of positive lymph nodes at 986 Postoperative Radiotherapy for Squamous Cell Carcinoma

4 neck dissection were as follows: none, 94%; one, 93%; two to three, 84%; four or more, 76% ( p =.02). There was a significantly reduced probability of neck control in patients with extracapsular extension (ECE) compared with those without ECE (the only patients included were those whose pathology report specifically commented on the presence or absence of ECE): 78% versus 94%, respectively ( p =.02). Locoregional Control According to Primary Site. Five-year actuarial locoregional control rates according to primary site were as follows: oral tongue, 72%; floor of mouth, 78%; retromolar trigone, 75%; and other sites, 61% ( p =.23). Time to Locoregional Failure. Locoregional failure developed in 55 patients (24%). Fifty (91%) of 55 recurrences were detected within 2 years of the date of surgery. The median time to recurrence was 5.4 months. Locoregional Control According to AJCC Stage. Five-year actuarial locoregional control rates according to clinical AJCC stage were as follows: stage I, 87%; stage II, 74%; stage III, 68%; and stage IV, 72% (p =.6). Five-year actuarial locoregional control rates according to pathologic AJCC stage are shown in Figure 1. Locoregional Control According to Margin Status. Five-year actuarial locoregional control rates according to margin status were as follows: negative margins, 77%; positive margins, 52%; and close/ equivocal, 86% ( p <.0001). Locoregional control results for patients with positive margins who received twice-a-day irradiation to 74.4 Gy or more were higher than for FIGURE 2. Locoregional control for positive margins versus dose. those treated once a day and/or to less than 74.4 Gy (Figure 2). Locoregional Control According to Other Pathologic Variables. Five-year actuarial locoregional control rates were significantly worse in patients with ECE, perineural invasion, or pathologic T3 or T4 tumors. There were no significant differences in 5-year locoregional control rates in patients with vascular invasion, bone invasion, or poor differentiation (Table 3). In addition, the number of lymph nodes involved did not significantly affect 5-year locoregional control rates ( p =.30): none, 78%; one, 75%; two to three, 74%; and four or more, 65%. Disease in 10 of the 12 patients with none of the usual indications for postoperative radiation was locoregionally controlled. Locoregional Control According to Number of Indications for Irradiation. Five-year actuarial locoregional control rates were significantly worse in patients with three or more indications for ad- Table 3. Univariate analysis of 5-year locoregional control. Risk factor % of locoregional control with listed factor (no. patients) % of locoregional control without listed factor (no. patients) p value T3/T4 primary* 63 (133) 86 (93).0003 Positive margins 52 (68) 77 (83).0018 Perineural invasion 62 (83) 88 (40).003 ECE 61 (43) 87 (42).007 z 3 risk factors 63 (49) 79 (177).007 Bone invasion 67 (80) 76 (146).24 Vascular invasion 70 (49) 76 (46).40 Poor differentiation 76 (47) 72 (179).57 FIGURE 1. Locoregional control versus pathologic AJCC stage. Abbreviation: ECE, extracapsular nodal spread. *pt1, 88%; pt2, 86%; pt3, 64%; pt4, 63%. Postoperative Radiotherapy for Squamous Cell Carcinoma 987

5 ministering postoperative irradiation (Figure 3). A steady decline was observed in the rates of locoregional control with an increase in the number of indications for administering postoperative irradiation (Table 4). On the basis of these findings, patients were divided into relatively favorable and unfavorable groups. Patients in the favorable group had fewer than three indications to receive irradiation; those in the unfavorable group had three or more indications. Multivariate Analysis of Pathologic Variables Affecting Locoregional Control. A multivariate analysis of pathologic factors that might influence locoregional control is shown in Table 5. T classification, margin status, and the presence of ECE, vascular or perineural invasion were significant. Time Analyses. Treatment time was analyzed in three ways to determine its influence on locoregional control. First, the interval (in days) between surgery and the beginning of irradiation was analyzed (Table 6). Data were analyzed by four time periods, which were chosen for statistical reasons to give near equal numbers of patients in each group. Patients were separated into low (< three indications for RT) and high (z three indications for RT) risk groups. There was a trend toward higher failure rates in highrisk patients whose irradiation was initiated more than 51 days after surgery (Figure 4). No trend was seen in low-risk patients (0 35 days, 23%; days, 4%; days, 30%; and >51 days, 17%). Second, the length of the overall treatment package, calculated from the date of surgery until the last day of irradiation, was analyzed for its prognostic impact (Table 6). In high-risk patients, there was a trend toward higher failure rates when the overall treatment time exceeded 101 days (Figure 5). For low-risk patients, the failure rates were not significantly Table 4. Locoregional control by indications for postoperative radiation therapy. No. of indications No. of recurrences/no. of patients % locoregional control 0 2/ / / / / / /5 40 different according to length of the overall treatment package (0 80 days, 19%; days, 16%; days, 28%; and >101 days, 17%). The length of the radiation course (in days) was analyzed for its potential impact on locoregional control. No trend was identified for either lowrisk or high-risk patient groups. Dose Analysis. Five-year locoregional control rates for patients who received 60 Gy or less (74%), > 60 to 65 Gy (84%), > 65 to 70 Gy (69%), or more than 70 Gy (63%) were similar because of patient selection ( p =.07). Patients with positive margins received higher mean doses (72 Gy) than did those with negative margins (64.8 Gy), yet still had lower locoregional control rates (63% vs 82%) at 5 years. Conversely, patients with close/ equivocal margins had the highest control rate (92%), their less favorable prognosis being offset by higher mean doses (66 Gy) ( p =.0004). Salvage of Locoregional Recurrence. Of 55 patients with locoregional failures, surgical salvage with or without additional irradiation was attempted in 17 (31%). Nine of 17 patients (53%) Table 5. Multivariate analysis of pathologic variables affecting locoregional control. FIGURE 3. Locoregional control versus number of risk factors. Risk factor p value T classification.0002 ECE.0037 Margins.0102 Perineural invasion.0103 Vascular invasion.0258 N status.1108 Overall stage.1541 Bone invasion.3045 Differentiation.5916 Abbreviation: ECE, extracapsular nodal spread. 988 Postoperative Radiotherapy for Squamous Cell Carcinoma

6 Table 6. Locoregional failure by surgery radiation therapy interval and overall treatment time. By no. of risk factors No. of failures/total no. Overall of patients (% failure) No. of failures/total no. patients (% failure) 0 2 z 3 Surgery RT interval in days /56 (25) 8/35 (23) 6/21 (29) /57 (16) 1/23 (4) 8/34 (24) /57 (28) 9/30 (30) 7/27 (26) >51 16/56 (29) 6/36 (17) 10/20 (50) Overall treatment time in days /60 (23) 6/32 (19) 8/28 (29) /56 (20) 5/32 (16) 6/24 (25) /54 (26) 7/25 (28) 7/29 (24) z101 16/56 (29) 6/35 (17) 10/21 (48) Abbreviation: RT, radiation therapy. were successfully salvaged, for an overall salvage rate of 16% (nine of 55 patients). Distant Metastasis. Five-year actuarial distant metastasis-free survival by pathologic AJCC stage was as follows: stage I, 100%; stage II, 97%; stage III, 90%; and stage IV, 81% (p =.07). In patients with positive nodes, those with ECE had significantly lower distant metastasis free survival rates (64%) than did those without ECE (95%, p =.001). Survival. Actuarial 5-year absolute and causespecific survival rates for the entire group were 47% and 67%, respectively. Absolute 5-year survival rates by pathologic AJCC stage were as follows: stage I, 63%; stage II, FIGURE 5. Locoregional control versus overall treatment time (patients with z three risk factors). 70%; stage III, 48%; and stage IV, 40% ( p =.03). Node-positive patients with ECE had a significantly lower absolute survival rate (21%) than did those without ECE (58%; p =.0003). Cause-specific survival rates at 5 years by clinical AJCC stage were as follows: stage I, 81%; stage II, 77%; stage III, 62%; and stage IV, 63% (p =.30). Cause-specific survival rates at 5 years by pathologic AJCC stage are shown in Figure 6. Node-positive patients with ECE had a significantly lower 5-year cause-specific survival (38%) than those without ECE had (81%, p <.0001). There was a significant improvement in 5-year cause-specific survival for patients without perineural invasion (85%) compared with those in whom it was present (56%, p =.002). A multivariate analysis of pathologic factors that might influence cause-specific survival is shown in Table 7. The presence of ECE or perineural invasion was significant. Postirradiation, Late Complications. Complications of treatment were graded in severity as mild, moderate, or severe. Mild complications were those that healed spontaneously in 1 to 5 months and were most often small (V0.5 cm) FIGURE 4. Locoregional control versus surgery radiation therapy interval (patients with z three risk factors). FIGURE 6. Cause-specific survival versus pathologic AJCC stage. Postoperative Radiotherapy for Squamous Cell Carcinoma 989

7 Table 7. Multivariate analysis of pathologic variables affecting cause-specific survival. Risk factor p value ECE.0001 Perineural invasion.0205 T classification.0612 Vascular invasion.2040 Differentiation.2599 Bone invasion.5086 Overall stage.4521 N status.6982 Margins.8837 Abbreviation: ECE, extracapsular nodal spread. areas of soft tissue necrosis or bone exposure. Moderate complications were of longer duration and produced more disability, yet resolved after conservation measures to promote healing such as discontinuation of denture use, oral rinses, antibiotics, and, in some instances, hyperbaric oxygen, without requiring surgery. Severe complications required hospitalization, surgery, or both. Patients requiring a permanent gastrostomy tube were also coded as having a severe complication. There were 58 mild and moderate complications (26%): 22 bone exposures, 21 soft tissue necroses, one small wound dehiscence, seven fistulas, and seven wound infections. There were 33 severe injuries (15%): 14 osteoradionecrosis, seven permanent gastrostomies, four severe dehiscences, three fistulas, two soft tissue necrosis, one wound infection, one mandibular fracture, and one plate extrusion. The median dose was 66 Gy in patients with severe complications. Logistics regression showed no correlation with respect to total dose (p = 0.81) or fractionation ( p = 0.25) (twice daily vs once daily) in patients experiencing severe complications. DISCUSSION The usual indications to give postoperative irradiation at the University of Florida for carcinoma of the oral cavity include one or more of the following pathologic findings related to the primary site: bone invasion or extension of tumor into the soft tissues of the neck (T4 primary); margins that are positive, close (V5 mm), contain CIS or dysplasia, or that were initially positive (but ultimately negative after re-resection 6 9 ;) perineural invasion; vascular space invasion; 13 or multicentricity (scattered, discontinuous foci or islands of tumor adjacent to the primary site, making margins of resection uncertain). Factors in the neck specimen for which postoperative irradiation is generally added include multiple positive lymph nodes or ECE. 13,16,18 21 High risk of occult tumor in an undissected, clinically negative N0 neck is not an adequate reason to add adjuvant RT unless additional indications for treatment are present. The high-risk neck should be electively dissected. Some of these factors are more ominous than others. For example, early bone erosion of the mandible is not likely to have the same negative prognostic influence as positive margins. Factors thought to be particularly ominous are the presence of positive margins, 7,22,23 multiple indications for administering postoperative irradiation, 22,24,25 and/or ECE. 17,19 21,23,25 27 Although we have never used poor differentiation as the sole indication for postoperative irradiation, there are data to suggest it may significantly affect locoregional control, 13,17,24 and in otherwise borderline cases, poor differentiation might be a reason to add irradiation postoperatively. This series shows statistically significant correlations on univariate analysis between locoregional control and T classification (T1 and T2 vs T3 and T4), pathologic AJCC stage, ECE, perineural invasion, margin status, and the number of indications for postoperative radiation (Table 3). Multivariate analysis shows T classification, margin status, and the presence of ECE, vascular or perineural invasion to be independent predictors of locoregional control (Table 5). Does Postoperative Radiotherapy Improve Locoregional Control and Survival? No randomized trials have addressed the efficacy of postoperative adjuvant RT. Some of the best available data are from the Medical College of Virginia, where two groups of surgeons operated on patients with head and neck cancer: general surgical oncologists who used surgery alone and reserved RT for treatment of recurrent disease, and otolaryngologists who routinely sent patients with locally advanced disease for postoperative RT. 23 One hundred twenty-five of 441 patients treated surgically between 1982 and 1988 had ECE and/ or positive margins; 71 were treated with surgery alone, and 54 received postoperative RT. Patients were irradiated at 1.8 to 2.0 Gy per fraction with 60 Co or 4-MV x-rays to doses of 50 to Gy in 26 patients and to 60 Gy or more in the remainder. Local control rates at 3 years after surgery alone compared with surgery and RT were as 990 Postoperative Radiotherapy for Squamous Cell Carcinoma

8 follows: ECE, 31% and 66% ( p =.03); positive margins, 41% and 49% ( p =.04); and ECE and positive margins, 0% and 68% ( p =.001). A multivariate analysis of local control was performed evaluating the impact of T classification, N status, use of postoperative RT, the number of positive nodes, the number of nodes with ECE, primary site, microscopic and macroscopic ECE, and margin status. For the local control endpoint, use of postoperative RT ( p =.0001), macroscopic ECE ( p =.0001), and margin status ( p =.09) were of independent significance. Disease-free survival at 3 years was 25% after surgery alone and 45% after combined-modality treatment ( p =.0001). Cause-specific survival rates at 3 years were 41% for surgery alone and 72% for surgery and postoperative RT ( p =.0003). Multivariate analysis of cause-specific survival showed postoperative RT ( p =.0001) and the number of nodes with ECE (p =.0001) significantly influenced this endpoint. Two irradiated patients experienced mandibular necrosis; one was treated with hyperbaric oxygen treatments and the other with conservative management. Lundahl et al 28 reported a series of 95 patients with node-positive squamous cell carcinoma who were treated with a neck dissection and postoperative RT at the Mayo Clinic. A matched-pair analysis was performed with a series of patients treated with surgery alone; 56 matched pairs of patients were identified. The rates of recurrence in the dissected neck (relative risk [RR] = 5.82; p =.0002), recurrence in either side of the neck (RR = 2.21; p =.0052), and death from any cause (RR = 1.67; p =.0182) were significantly higher for patients treated with neck dissection alone. Thus, it seems for patients who are at high risk for locoregional failure after surgery, postoperative RT significantly improves disease control above the clavicles as well as survival. Factors Affecting Locoregional Control. Data from the University of Florida, 22 the Radiation Therapy Oncology Group (RTOG) trial, 29 and The University of Texas M. D. Anderson Cancer 25,30 33 Center all suggest locoregional control rates after postoperative irradiation are lower for oral cavity primary tumors than for other head and neck primary sites. Zelefsky et al 34 noted that among patients with oral cavity primary tumors, those with oral tongue lesions fared the worst (p =.03). In this series, there were no significant differences according to primary site within the oral cavity. Another treatment-related issue that may influence the likelihood of cure is beam energy. Data exist in the literature suggesting better control in the neck with 60 Co and 4-MV than with 6-MV photons, although local and locoregional control is just as good or better with 6-MV beams. 35,36 Thus, most patients can be adequately treated with 6-MV photons. A beam spoiler may be added to increase the surface dose for patients believed to be at particularly high risk for tumor in the subcutaneous tissues. Salvage of Patients with Locoregional Recurrence. In this series, 55 patients (25%) who were treated had recurrence above the clavicles develop. Seventeen underwent salvage surgery with or without additional RT. Nine of 17 (53%) were successfully salvaged, for an overall salvage rate of 16% (nine of 55). Fifty-eight of 240 patients (24%) treated with surgery and postoperative RT at M. D. Anderson Cancer Center had a locoregional recurrence develop. 25 Thirty-six patients underwent salvage therapy with surgery alone or combined with chemotherapy (11 patients), RT alone or combined with chemotherapy (three patients), or chemotherapy alone (22 patients). Only one of 58 patients (2%) was a long-term survivor 22 months after salvage therapy. Analysis of Time and Dose Factors. Intuitively, it seems residual microscopic nests of tumor would be able to regrow in proportion to the length of time between surgery and the beginning of RT. However, the available data are mixed on this issue. 22,37 40 This study demonstrates a decrease in locoregional control for patients with three or more risk factors with surgery RT intervals greater than 51 days (Figure 4). Several authors have also suggested a correlation between tumor control and the length of RT, the latter being altered by the dose per fraction and/or number of fractions per day. 22,25,40 42 No such trend was detected in this series. These two indices (ie, the surgery RT interval and the length of the radiotherapy course) combine to give the overall treatment time, defined as the time from surgery to the last day of irradiation. Data exist in the literature correlating overall treatment time with local control, at least for high-risk patients. 40,43 This study demonstrates a decrease in locoregional control for patients having three or more risk factors with overall treatment times greater Postoperative Radiotherapy for Squamous Cell Carcinoma 991

9 than 101 days (Figure 5), although the difference is not statistically significant. The previously mentioned data and common sense indicate irradiation should begin as soon as healing is complete; it can often be started within 3 to 4 weeks of surgery. If irradiation is delayed until gross recurrence has occurred, the chance for successful salvage by irradiation is only 5% to 10%. 7,44,45 If healing is not complete by 6 weeks, data from earlier University of Florida series 43,46 show irradiation can often be safely initiated, and approximately two thirds of patients will heal spontaneously during or after irradiation. Patients at high risk (z three risk factors) for recurrence and/or those whose surgery RT interval has been prolonged (>7 weeks) should be considered for altered dose/fractionation schemes that shorten the length of the RT course, thereby decreasing the overall treatment time. Adjuvant Chemotherapy and Future Directions. The issue of whether chemotherapy is beneficial concomitantly with postoperative irradiation for head and neck cancer was recently resolved with the publication of two randomized trials (RTOG 9501 and EORTC 22391). 47,48 Each of these showed an improvement in locoregional control and disease-free survival with cisplatin (100 mg/m 2 ) given on days 1, 22, and 43 of the radiotherapy regimen. 47,48 Prior to that, two publications showed a similar benefit using concomitant chemoradiation, although an earlier review of the RTOG 9501 data that appeared in abstract form was inconclusive Severe acute effects are seen more frequently with concomitant treatment compared with postoperative radiation alone. Although none of the patients in this series received chemotherapy, our current policy is to consider concomitant cisplatin in selected highrisk cases. IMRT has been used postoperatively at other institutions We currently use IMRT mainly to treat de novo head and neck tumors definitively with irradiation. It is used sparingly in the postoperative setting, mainly because of concerns about the dose distribution to skin and subcutaneous tissues, which may be at more risk after surgery. As the role of IMRT evolves, its use may increase in postoperative situations. We continue to favor more conventional beam arrangements when feasible, to optimize dose distributions to the skin and subcutaneous tissues at risk. The data presented herein suggest a strikingly negative effect on locoregional control when perineural spread, ECE, and/or positive margins are present. More than one third of patients continue to have treatment failure above the clavicles when any of these three factors exist. An improvement in locoregional control was seen in patients with positive margins treated twice daily to doses of 74.4 Gy or higher. We will likely consider the same aggressive treatment for patients with oral cavity lesions with perineural and/or ECE, as well. Conversely, consideration should be given to re-resection in cases in which the final margins contain invasive cancer if the site of positivity can be accurately determined and another operation performed without adding excessively to the morbidity. Our current recommendation for patients with oral cavity primary tumors who require postoperative irradiation is to deliver 64 to 66 Gy at 2 Gy per fraction for relatively favorable situations and 74.4 to 76.8 Gy in 62 to 64 fractions, twice a day, for unfavorable scenarios. Concomitant cisplatin should be considered in high-risk cases. We recognize that these dosefractionation recommendations for high-risk patients are not strictly supported by our data or by randomized data published elsewhere in the literature. 25,40 However, we believe these guidelines are justified in view of the unsatisfactory rates of locoregional control seen in this unfavorable subset of patients. REFERENCES 1. MacComb WS, Fletcher GH. Planned combination of surgery and radiation in treatment of advanced primary head and neck cancers. Am J Roentgenol Radium Ther Nucl Med 1957;77: American Joint Committee on Cancer, American Cancer Society, American College of Surgeons. Fleming ID, et al, editors. AJCC cancer staging handbook from the AJCC Cancer Staging Manual, ed 5. Philadelphia: Lippincott- Raven, SAS Institute Inc. SAS OnlineDoc, Version 8. Cary, NC: SAS Institute Inc., Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Cox DR. Regression models and life tables series B (methodological). J R Stat Soc 1972;34: Chen TY, Emrich LJ, Driscoll DL. The clinical significance of pathological findings in surgically resected margins of the primary tumor in head and neck carcinoma. Int J Radiat Oncol Biol Phys 1987;13: Huang D, Johnson CR, Schmidt-Ullrich RK, Sismanis A, Neifeld JP, Weber J. Incompletely resected advanced squamous cell carcinoma of the head and neck: the effectiveness of adjuvant vs. salvage radiotherapy. Radiother Oncol 1992;24: Looser KG, Shah JP, Strong EW. The significance of positive margins in surgically resected epidermoid carcinomas. Head Neck Surg 1978;1: Scholl P, Byers RM, Batsakis JG, Wolf P, Santini H. Microscopic cut-through of cancer in the surgical treat- 992 Postoperative Radiotherapy for Squamous Cell Carcinoma

10 ment of squamous carcinoma of the tongue. Prognostic and therapeutic implications. Am J Surg 1986;152: Lydiatt DD, Robbins KT, Byers RM, Wolf PF. Treatment of stage I and II oral tongue cancer. Head Neck 1993;15: O Brien CJ, Lahr CJ, Soong SJ, et al. Surgical treatment of early-stage carcinoma of the oral tongue would adjuvant treatment be beneficial? Head Neck Surg 1986; 8: Soo KC, Carter RL, O Brien CJ, Barr L, Bliss JM, Shaw HJ. Prognostic implications of perineural spread in squamous carcinomas of the head and neck. Laryngoscope 1986;96: Close LG, Brown PM, Vutich MF, Reisch J, Schaefer SD. Microvascular invasion and survival in cancer of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg 1989;115: Farr HW, Arthur K. Epidermoid carcinoma of the mouth and pharynx J Laryngol Otol 1972; 86: Francheschi D, Gupta R, Spiro RH, Shah JP. Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 1993;166: O Brien CJ, Smith JW, Soong SJ, Urist MM, Maddox WA. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. Am J Surg 1986;152: Olsen KD, Caruso M, Foote RL, et al. Primary head and neck cancer. Histopathologic predictors of recurrence after neck dissection in patients with lymph node involvement. Arch Otolaryngol Head Neck Surg 1994;120: Cachin Y, Eschwege F. Combination of radiotherapy and surgery in the treatment of head and neck cancers. Cancer Treat Rev 1975;2: Johnson JT, Barnes EL, Myers EN, Schramm VL Jr, Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Otolaryngology 1981;107: Johnson JT, Myers EN, Bedetti CD, Barnes EL, Schramm VL, Thearle PB. Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. Arch Otolaryngol 1985;111: Synderman NL, Johnson JT, Schramm VL, Myers EN, Bedetti CD, Thearle PB. Extracapsular spread of carcinoma in cervical lymph nodes. Impact upon survival in patients with carcinoma of the supraglottic larynx. Cancer 1985;56: Amdur RJ, Parsons JT, Mendenhall WM, Million RR, Stringer SP, Cassisi NJ. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys 1989;16: Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys 1992;23: Foote RL, Buskirk SJ, Stanley RJ, et al. Patterns of failure after total laryngectomy for glottic carcinoma. Cancer 1989;64: Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26: Arriagada R, Eschwege F, Cachin Y, Richard JM. The value of combining radiotherapy alone with surgery in the treatment of hypopharyngeal and laryngeal cancers. Cancer 1983;51: Bartelink H, Breur K, Hart G, Annyas B, van Slooten E, Snow G. The value of postoperative radiotherapy as an adjuvant to radical neck dissection. Cancer 1983;52: Lundahl RE, Foote RL, Bonner JA, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1998;40: Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study of the Radiation Therapy Oncology Group. Head Neck Surg 1987; 10: El Badawi SA, Goepfert H, Fletcher GH, Herson J, Oswald MJ. Squamous cell carcinoma of the pyriform sinus. Laryngoscope 1982;92: Feldman M, Fletcher GH. Analysis for the parameters relating to failures above the clavicles in patients treated by postoperative irradiation for squamous cell carcinoma of the oral cavity or oropharynx. Int J Radiat Oncol Biol Phys 1982;8: Goepfert H, Jesse RH, Fletcher GH, Hamberger A. Optimal treatment for the technically resectable squamous cell carcinoma of the supraglottic larynx. Laryngoscope 1975;85: Hamberger AD, Fletcher GH, Guillamondegui OM, Byers RM. Advanced squamous cell carcinoma of the oral cavity and oropharynx treated with irradiation and surgery. Radiology 1976;119: Zelefsky MJ, Harrison LB, Fass DE, et al. Postoperative radiotherapy for oral cavity cancers: impact of anatomic subsite on treatment outcome. Head Neck 1990; 12: Aref A, Berkey BA, Schwade JG, et al. The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG Int J Radiat Oncol Biol Phys 2000;47: Fortin A, Allard J, Albert M, Roy J. Outcome of patients treated with cobalt and 6 MV in head and neck cancers. Head Neck 2001;23: Vikram B. Importance of the time interval between surgery and postoperative radiation therapy in the combined management of head and neck cancer. Int J Radiat Oncol Biol Phys 1979;5: Schiff PB, Harrison LB, Strong EW, et al. Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer. J Surg Oncol 1990;43: Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R. Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2001;49: Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51: Zelefsky MJ, Harrison LB, Fass DE, et al. Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: Impact of therapy on patients with positive surgical margins. Int J Radiat Oncol Biol Phys 1992;25: Pfreundner L, Willner J, Marx A, Hoppe F, Beckmann G, Flentje M. The influence of the radicality of resection and dose of postoperative radiation therapy on local control and survival in carcinomas of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2000;47: Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 1997;39: Ampil RL. Surgery and postoperative external irradiation for head and neck cancer recurrent after surgery alone. Laryngoscope 1998;98: Postoperative Radiotherapy for Squamous Cell Carcinoma 993

11 45. Fletcher GH, Evers WT. Radiotherapeutic management of surgical recurrences and postoperative residuals in tumors of the head and neck. Radiology 1970;95: Isaacs JH Jr, Stiles WA, Cassisi NJ, Million RR, Parsons JT. Postoperative radiation of open head and neck wounds updated. Head Neck 1997;19: Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350: Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004;350: Bachaud J-M, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36: Bernier J, Domenge C, Eschwege F, Ozsahin M, Matuszewska K, Moncho V, Greiner RH, Giralt J, Kirkpatrick A, van Glabbeke M. Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: Results of EORTC phase III trial [Abstr.] Int J Radiat Oncol Biol Phys 2001;51(3 Suppl. 1): Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, et al. Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: Initial report of RTOG 9501/intergroup phase III trial. [Abstr.] Presented at the 38 th Annual Meeting of the Am Soc Clin Oncol 2002, Orlando, FL. 52. Chao KS, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head and neck cancer. Int J Radiat Oncol Biol Phys 2003;55: Chao KS, Wippold FJ, Ozyigit G, et al. Determination and delineation of nodal target volumes for head and neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys 2002;53: Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. Radiother Oncol 2001;61: Dawson LA, Anzai Y, Marsh L, et al. Patterns of localregional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2000;46: Claus F, Vakaet L, De Gersem W, et al. Postoperative radiotherapy of paranasal sinus tumours: A challenge for intensity-modulated radiotherapy. Acta Otorhinolaryngol Belg 1999;53: Postoperative Radiotherapy for Squamous Cell Carcinoma

ACR Appropriateness Criteria Adjuvant Therapy for Resected Squamous Cell Carcinoma of the Head and Neck EVIDENCE TABLE

ACR Appropriateness Criteria Adjuvant Therapy for Resected Squamous Cell Carcinoma of the Head and Neck EVIDENCE TABLE 1. Johnson JT, Barnes EL, Myers EN, Schramm VL, Jr., Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 1981; 107(1):75-79.. Snow GB, Annyas AA,

More information

THE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER

THE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER THE IMPACT OF THE TIME FACTOR ON THE OUTCOME OF A COMBINED TREATMENT OF PATIENTS WITH LARYN- GEAL CANCER Piotr Milecki 1, Grażyna Stryczyńska 1, Aleksandra Kruk-Zagajewska 2 Department of Radiotherapy,

More information

The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins

The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins Original Article The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins Badakh Dinesh K, Grover Amit H Dr. D.

More information

Accepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.

Accepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience (  DOI: /hed. DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,

More information

Protocol of Radiotherapy for Head and Neck Cancer

Protocol of Radiotherapy for Head and Neck Cancer 106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high

More information

Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers

Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers ORIGINAL ARTICLE Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers Benjamin H. Lok, MD, 1 Christine Chin, BS, 1 Nadeem Riaz, MD, 1 Felix Ho, MD, 1 Man Hu, MD, 1 Julian C. Hong,

More information

RANDOMIZED TRIAL ADDRESSING RISK FEATURES AND TIME FACTORS OF SURGERY PLUS RADIOTHERAPY IN ADVANCED HEAD-AND-NECK CANCER

RANDOMIZED TRIAL ADDRESSING RISK FEATURES AND TIME FACTORS OF SURGERY PLUS RADIOTHERAPY IN ADVANCED HEAD-AND-NECK CANCER PII S0360-3016(01)01690-X Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 3, pp. 571 578, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front

More information

The two main treatment modalities for patients with

The two main treatment modalities for patients with Review Clinical Medicine & Research Volume 4, Number 3: 200-208 2006 Marshfield Clinic http://www.clinmedres.org Postoperative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck William M. Mendenhall,

More information

Neck Dissection. Asst Professor Jeeve Kanagalingam MA (Cambridge), BM BCh (Oxford), MRCS (Eng), DLO, DOHNS, FRCS ORL-HNS (Eng), FAMS (ORL)

Neck Dissection. Asst Professor Jeeve Kanagalingam MA (Cambridge), BM BCh (Oxford), MRCS (Eng), DLO, DOHNS, FRCS ORL-HNS (Eng), FAMS (ORL) Neck Dissection Asst Professor Jeeve Kanagalingam MA (Cambridge), BM BCh (Oxford), MRCS (Eng), DLO, DOHNS, FRCS ORL-HNS (Eng), FAMS (ORL) History radical neck Henry Butlin proposed enbloc removal of upper

More information

ORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx

ORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;

More information

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no

More information

Survival impact of cervical metastasis in squamous cell carcinoma of hard palate

Survival impact of cervical metastasis in squamous cell carcinoma of hard palate Vol. 116 No. 1 July 2013 Survival impact of cervical metastasis in squamous cell carcinoma of hard palate Quan Li, MD, a Di Wu, MD, b,c Wei-Wei Liu, MD, PhD, b,c Hao Li, MD, PhD, b,c Wei-Guo Liao, MD,

More information

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised. Case Scenario 1 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of

More information

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;

More information

RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.

RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL

More information

Lymph node ratio as a prognostic factor in head and neck cancer patients

Lymph node ratio as a prognostic factor in head and neck cancer patients Chen et al. Radiation Oncology (2015) 10:181 DOI 10.1186/s13014-015-0490-9 RESEARCH Open Access Lymph node ratio as a prognostic factor in head and neck cancer patients Chien-Chih Chen 1*, Jin-Ching Lin

More information

Pre- Versus Post-operative Radiotherapy

Pre- Versus Post-operative Radiotherapy Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology

More information

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised. Case Scenario 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of alcohol.

More information

IDENTIFICATION OF A HIGH-RISK GROUP AMONG PATIENTS WITH ORAL CAVITY SQUAMOUS CELL CARCINOMA AND pt1 2N0 DISEASE

IDENTIFICATION OF A HIGH-RISK GROUP AMONG PATIENTS WITH ORAL CAVITY SQUAMOUS CELL CARCINOMA AND pt1 2N0 DISEASE doi:10.1016/j.ijrobp.2010.09.036 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 284 290, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front

More information

Lymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer

Lymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer ORIGINAL ARTICLE Lymph node density as an independent prognostic factor in node-positive patients with tonsillar cancer Jun-Ook Park, MD, PhD, 1 Young-Hoon Joo, MD, PhD, 2 Kwang-Jae Cho, MD, PhD, 2 Min-Sik

More information

MANAGEMENT OF CA HYPOPHARYNX

MANAGEMENT OF CA HYPOPHARYNX MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable

More information

Clinical Study Regional Failures after Selective Neck Dissection in Previously Untreated Squamous Cell Carcinoma of Oral Cavity

Clinical Study Regional Failures after Selective Neck Dissection in Previously Untreated Squamous Cell Carcinoma of Oral Cavity International Surgical Oncology, Article ID 205715, 8 pages http://dx.doi.org/10.1155/2014/205715 Clinical Study Regional Failures after Selective Neck Dissection in Previously Untreated Squamous Cell

More information

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV

More information

The management of advanced supraglottic and

The management of advanced supraglottic and ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1

More information

Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation

Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation 1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing

More information

Laryngeal Conservation

Laryngeal Conservation Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction

More information

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 Head and Neck Coding and Staging Head and Neck Coding and Staging Anatomy & Primary Site Sequencing and MPH

More information

Locoregional recurrences are the most frequent

Locoregional recurrences are the most frequent ORIGINAL ARTICLE SECOND SALVAGE SURGERY FOR RE-RECURRENT ORAL CAVITY AND OROPHARYNX CARCINOMA Ivan Marcelo Gonçalves Agra, MD, PhD, 1 João Gonçalves Filho, MD, PhD, 2 Everton Pontes Martins, MD, PhD, 2

More information

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.

More information

Oral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment

Oral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment Oral Cavity 1. Introduction 1.1 General Information and Aetiology The oral cavity extends from the lips to the palatoglossal folds and consists of the anterior two thirds of the tongue, floor of the mouth,

More information

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,

More information

TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER

TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf,

More information

Self-Assessment Module 2016 Annual Refresher Course

Self-Assessment Module 2016 Annual Refresher Course LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns

More information

(loco-regional disease)

(loco-regional disease) (loco-regional disease) (oral cavity) (circumvillae papillae) (subsite) A (upper & lower lips) B (buccal membrane) C (mouth floor) D (upper & lower gingiva) E (hard palate) F (tongue -- anterior 2/3 rds

More information

Oral cavity cancer Post-operative treatment

Oral cavity cancer Post-operative treatment Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection

More information

Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer

Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer ORIGINAL ARTICLE Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer Paul A. Tennant, MD, * Elizabeth Cash, PhD, Jeffrey M. Bumpous, MD, Kevin L. Potts,

More information

EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA

EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA ORIGINAL ARTICLE EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA Raymond King Yin Tsang, FRCSEd, Joseph Chun Kit Chung, MRCSEd, Yiu Wing

More information

Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations

Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Troy G. Scroggins Jr. MD Chairman, Department of Radiation Oncology Ochsner Health Systems 1 Association of Postoperative Radiotherapy

More information

ORIGINAL ARTICLE. Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD

ORIGINAL ARTICLE. Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD ORIGINAL ARTICLE Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Harold Lau, MD; Tien Phan, MD; Jack MacKinnon,

More information

Locally advanced head and neck cancer

Locally advanced head and neck cancer Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary

More information

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed

More information

AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx

AJCC Cancer Staging 8 th edition. Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC Cancer Staging 8 th edition Lip and Oral Cavity Oropharynx (p16 -) and Hypopharynx Larynx AJCC 7 th edition Lip and Oral cavity Pharynx Larynx KEY CHANGES Skin of head and neck (Vermilion of the lip)

More information

FACULTY OF MEDICINE SIRIRAJ HOSPITAL

FACULTY OF MEDICINE SIRIRAJ HOSPITAL Neck Dissection Pornchai O-charoenrat MD, PhD Division of Head, Neck and Breast Surgery Department of Surgery FACULTY OF MEDICINE SIRIRAJ HOSPITAL Introduction Status of the cervical lymph nodes is the

More information

PROGNOSTIC INDICATORS FOR SURVIVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS: ANALYSIS OF A SERIES OF 621 CASES

PROGNOSTIC INDICATORS FOR SURVIVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS: ANALYSIS OF A SERIES OF 621 CASES PROGNOSTIC INDICATORS FOR SURVIVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS: ANALYSIS OF A SERIES OF 621 CASES Christophe Le Tourneau, MD, 1 Michel Velten, MD, PhD, 1,2 Guy-Michel Jung, MD, 2 Guy Bronner,

More information

Original article. Parotid squamous cell carcinoma: Is it a primary or secondary? Aboziada A Mohamed and Eisbruch, Avraham.

Original article. Parotid squamous cell carcinoma: Is it a primary or secondary? Aboziada A Mohamed and Eisbruch, Avraham. Original article Kasr El-aini J. Clin. Oncol. nucl. med. vol. 7, no. -2, Jan.-April. 2:57-6 Parotid squamous cell carcinoma: Is it a primary or secondary? Aboziada A Mohamed and Eisbruch, Avraham. Department

More information

PRINCIPLES OF RADIATION ONCOLOGY

PRINCIPLES OF RADIATION ONCOLOGY PRINCIPLES OF RADIATION ONCOLOGY Ravi Pachigolla, MD Faculty Advisor: Anna Pou, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation January 5, 2000 HISTORY

More information

Salivary Glands tumors

Salivary Glands tumors Salivary Glands tumors Sal.Gl. 1 Salivary Glands tumors Work-up procedure TNM staging Primary treatment Follow-up Treatment of recurrent and/or metastatic disease References Sal.Gl. 2 Standard clinical

More information

Oral Cavity Cancer Combined modality therapy

Oral Cavity Cancer Combined modality therapy Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no

More information

Title. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information

Title. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal

More information

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed

More information

Oral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi

Oral cancer: Prognosis & Treatment. Dr. Hani Al Sheikh Radhi Oral cancer: Prognosis & Treatment Dr. Hani Al Sheikh Radhi Prognostic factors in Oral caner TNM staging T stage N stage M stage Site Histological Factors Vascular & Perineural Invasion Surgical Margins

More information

Is an Elective Neck Dissection Necessary for All Cases of N0 Oral Squamous Cell Carcinoma?

Is an Elective Neck Dissection Necessary for All Cases of N0 Oral Squamous Cell Carcinoma? Tokai J Exp Clin Med., Vol. 41, No. 3, pp. 112-117, 2016 Is an Elective Neck Dissection Necessary for All Cases of N0 Oral Squamous Cell Carcinoma? Elective Neck Dissection may be Performed for Tongue

More information

Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp

Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp Wray et al. Radiation Oncology (2015) 10:199 DOI 10.1186/s13014-015-0509-2 RESEARCH Open Access Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp Justin

More information

ORIGINAL ARTICLE. Levels II and III neck dissection for larynx cancer with N0 neck

ORIGINAL ARTICLE. Levels II and III neck dissection for larynx cancer with N0 neck Braz J Otorhinolaryngol. 2012;78(5):59-63. ORIGINAL ARTICLE.org BJORL Levels II and III neck dissection for larynx cancer with N0 neck Carlos Takahiro Chone 1, Hugo Fontana Kohler 2, Rodrigo Magalhães

More information

Introduction. Jong Hoon Lee, MD 1. Sang Nam Lee, MD 2 Jin Hyoung Kang, MD 3 Min Sik Kim, MD 4 Dong Il Sun, MD 2 Yeon-Sil Kim, MD 2

Introduction. Jong Hoon Lee, MD 1. Sang Nam Lee, MD 2 Jin Hyoung Kang, MD 3 Min Sik Kim, MD 4 Dong Il Sun, MD 2 Yeon-Sil Kim, MD 2 pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2013;45(1):31-39 Original Article http://dx.doi.org/10.4143/crt.2013.45.1.31 Open Access Adjuvant Postoperative Radiotherapy with or without Chemotherapy

More information

Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX

Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21

More information

Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience

Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience Original Article Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience Öztun Temelli, Ersoy Kekilli 2, Ahmet Kızılay Department of Radiation Oncology, 2 Department of

More information

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo

More information

Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary

Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary Original article Annals of Oncology 14: 1306 1311, 2003 DOI: 10.1093/annonc/mdg330 Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary A. Argiris

More information

Research Article Planned Neck Dissection Following Radiation Treatment for Head and Neck Malignancy

Research Article Planned Neck Dissection Following Radiation Treatment for Head and Neck Malignancy Hindawi Publishing Corporation International Journal of Otolaryngology Volume 22, Article ID 95423, 5 pages doi:5/22/95423 Research Article Planned Neck Dissection Following Radiation Treatment for Head

More information

Elective neck treatment in clinically node-negative paranasal sinus carcinomas: impact on treatment outcome

Elective neck treatment in clinically node-negative paranasal sinus carcinomas: impact on treatment outcome Original Article Radiat Oncol J 218;36(4):34-316 https://doi.org/1.3857/roj.218.416 pissn 2234-19 eissn 2234-3156 Elective neck treatment in clinically node-negative paranasal sinus carcinomas: impact

More information

Post-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer

Post-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for

More information

Accepted 11 April 2008 Published online 16 September 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.

Accepted 11 April 2008 Published online 16 September 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed. ORIGINAL ARTICLE NODAL METASTASES AT LEVEL IIb DURING NECK DISSECTION FOR HEAD AND NECK CANCER: CLINICAL AND PATHOLOGIC EVALUATION Roberto Santoro, MD, 1 Alessandro Franchi, MD, 2 Oreste Gallo, MD, 1 Giulia

More information

Accepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179

Accepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179 ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS

More information

The buccal mucosa includes all the intraoral mucosal. Carcinoma of the buccal mucosa

The buccal mucosa includes all the intraoral mucosal. Carcinoma of the buccal mucosa Carcinoma of the buccal mucosa DINESH K. CHHETRI, MD, JEFFREY D. RAWNSLEY, MD, and THOMAS C. CALCATERRA, MD, Los Angeles, California OBJECTIVE: The goal was to analyze the outcome of surgical therapy for

More information

Clinical analysis of 29 cases of nasal mucosal malignant melanoma

Clinical analysis of 29 cases of nasal mucosal malignant melanoma 1166 Clinical analysis of 29 cases of nasal mucosal malignant melanoma HUANXIN YU and GANG LIU Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China

More information

Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer

Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Dylan F. Roden, MD, MPH 1,2 ; David Schreiber, MD 2,3 ; and Babak Givi, MD 1,2 BACKGROUND: Concurrent chemoradiation (CCRT) and upfront

More information

Protons for Head and Neck Cancer. William M Mendenhall, M.D.

Protons for Head and Neck Cancer. William M Mendenhall, M.D. Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major

More information

ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER

ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4

More information

Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer

Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer 1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study

More information

Sanguineti s (2)Comment: When it was initially published in 2003 with a median follow-up of 3.8 years (4), the RTOG study led to a change in

Sanguineti s (2)Comment: When it was initially published in 2003 with a median follow-up of 3.8 years (4), the RTOG study led to a change in Commento di due Soci AIRO pubblicati su due prestigiose riviste internazionali al Trial della forastiere et al. Long term results of RTOG:91-11 (a cura di Dr. Russi e Dr. Testolin )! Forastiere)et)al.)Long/Term)Results)of)RTOG)91/11:)A)Comparison)of)

More information

The current treatment for oral cancer is wide

The current treatment for oral cancer is wide ORIGINAL ARTICLE RARE INVOLVEMENT OF SUBMANDIBULAR GLAND BY ORAL SQUAMOUS CELL CARCINOMA Tseng-Cheng Chen, MD, 1 Wu-Chia Lo, MD, 1 Jenq-Yuh Ko, MD, PhD, 1 Pei-Jen Lou, MD, PhD, 1 Tsung-Lin Yang, MD, 1,2

More information

Fan et al. Radiation Oncology (2017) 12:184 DOI /s

Fan et al. Radiation Oncology (2017) 12:184 DOI /s Fan et al. Radiation Oncology (2017) 12:184 DOI 10.1186/s13014-017-0910-0 RESEARCH Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three

More information

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina

More information

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome

More information

UPDATE ON RADIOTHERAPY

UPDATE ON RADIOTHERAPY 1 Miriam Kleiter UPDATE ON RADIOTHERAPY Department for Companion Animals and Horses, Plattform Radiooncology and Nuclear Medicine, University of Veterinary Medicine Vienna Introduction Radiotherapy has

More information

Accepted 19 May 2008 Published online 2 September 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.20912

Accepted 19 May 2008 Published online 2 September 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.20912 ORIGINAL ARTICLE OUTCOMES FOLLOWING PAROTIDECTOMY FOR METASTATIC SQUAMOUS CELL CARCINOMA WITH MICROSCOPIC RESIDUAL DISEASE: IMPLICATIONS FOR FACIAL NERVE PRESERVATION N. Gopalakrishna Iyer, MBBS (Hons),

More information

Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.

Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and

More information

RECURRENCE in the neck is a

RECURRENCE in the neck is a ORIGINAL ARTICLE Efficacy of Targeted Chemoradiation and Planned Selective Neck Dissection to Control Bulky Nodal Disease in Advanced Head and Neck Cancer K. Thomas Robbins, MD; Frank S. H. Wong, MD; Parvesh

More information

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. American Society of Clinical Oncology Clinical Practice Guideline

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. American Society of Clinical Oncology Clinical Practice Guideline Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer American Society of Clinical Oncology Clinical Practice Guideline Introduction ASCO convened an Expert Panel to develop recommendations

More information

Head and Neck Reirradiation: Perils and Practice

Head and Neck Reirradiation: Perils and Practice Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of

More information

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,

More information

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases

Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation

More information

SALIVARY GLAND TUMORS TREATED WITH ADJUVANT INTENSITY-MODULATED RADIOTHERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY

SALIVARY GLAND TUMORS TREATED WITH ADJUVANT INTENSITY-MODULATED RADIOTHERAPY WITH OR WITHOUT CONCURRENT CHEMOTHERAPY doi:10.1016/j.ijrobp.2010.09.042 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 308 314, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front

More information

A Rule-based Model for Local and Regional Tumor Spread

A Rule-based Model for Local and Regional Tumor Spread A Rule-based Model for Local and Regional Tumor Spread Ira J. Kalet, Ph.D., Mark Whipple, M.D., M.S., Silvia Pessah, M.D., M.Ph., Jerry Barker, M.D., Mary M. Austin-Seymour, M.D., Linda G. Shapiro, Ph.D.

More information

Cancer of the Oral Cavity

Cancer of the Oral Cavity The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology Cancer of the Oral Cavity Ashok Shaha Principals of Management of Oral Cancer A)

More information

ORIGINAL ARTICLE. Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma

ORIGINAL ARTICLE. Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma ORIGINAL ARTICLE Transoral Robotic-Assisted Surgery for Head and Neck Squamous Cell Carcinoma One- and 2-Year Survival Analysis Hilliary N. White, MD; Eric J. Moore, MD; Eben L. Rosenthal, MD; William

More information

Adenoid Cystic Carcinoma Minor Salivary Gland Origin

Adenoid Cystic Carcinoma Minor Salivary Gland Origin Adenoid Cystic Carcinoma Minor Salivary Gland Origin Educational Session Presenter: Smith JA Supervisors: Palme CE, Gupta R Content Case report Imaging Primary Therapy Surgery Adjuvant Therapy Radiotherapy

More information

Q&A. Fabulous Prizes. Collecting Cancer Data: Pharynx 12/6/12. NAACCR Webinar Series Collecting Cancer Data Pharynx

Q&A. Fabulous Prizes. Collecting Cancer Data: Pharynx 12/6/12. NAACCR Webinar Series Collecting Cancer Data Pharynx Collecting Cancer Data Pharynx NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar

More information

Cancer Medicine. Introduction. Open Access ORIGINAL RESEARCH

Cancer Medicine. Introduction. Open Access ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience

More information

Sino-nasal Cancer in Denmark 1982 ± 1991

Sino-nasal Cancer in Denmark 1982 ± 1991 ORIGINAL ARTICLE Sino-nasal Cancer in Denmark 1982 ± 1991 A Nationwide Sur ey Cai Grau, Mikkel Holmelund Jakobsen, Grethe Harbo, Viggo Svane-Knudsen, Kim Wedervang, Susanne Kornum Larsen and Carsten Rytter

More information

Accepted 19 February 2010 Published online 19 May 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI: /hed.21436

Accepted 19 February 2010 Published online 19 May 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI: /hed.21436 ORIGINAL ARTICLE FREQUENCY OF BILATERAL CERVICAL METASTASES IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE ANALYSIS OF 352 CASES AFTER BILATERAL NECK DISSECTION Bernhard Olzowy, MD, 1 Yulia

More information

Survey of Laryngeal Cancer at SBUH comparing 108 cases seen here from to the NCDB of 9,256 cases diagnosed nationwide in 2000

Survey of Laryngeal Cancer at SBUH comparing 108 cases seen here from to the NCDB of 9,256 cases diagnosed nationwide in 2000 Survey of Laryngeal Cancer at comparing 108 cases seen here from 1998 2002 to the of 9,256 cases diagnosed nationwide in 2000 Stony Brook University Hospital Cancer Program Annual Report 2002-2003 Gender

More information

Mick Spillane. Medical. Intensity-Modulated Radiotherapy for Sinonasal Tumors

Mick Spillane. Medical. Intensity-Modulated Radiotherapy for Sinonasal Tumors Mick Spillane Medical Formatted: Left Intensity-Modulated Radiotherapy for Sinonasal Tumors F Division of Radiotherapy, Department of Oncology (I. M., L. V., W. D. N.), and Division of Head and Neck Surgery,

More information

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4

More information

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and

More information

Definitive radiotherapy for cervical esophageal cancer

Definitive radiotherapy for cervical esophageal cancer ORIGINAL ARTICLE Definitive radiotherapy for cervical esophageal cancer Caineng Cao, MD, Jingwei Luo, MD, * Li Gao, MD, Guozhen Xu, MD, Junlin Yi, MD, Xiaodong Huang, MD, Kai Wang, MD, Shiping Zhang, MD,

More information

Treatment and prognosis of patients with recurrent laryngeal carcinoma: a retrospective study

Treatment and prognosis of patients with recurrent laryngeal carcinoma: a retrospective study Page 1 of 7 Treatment and prognosis of patients with recurrent laryngeal carcinoma: a retrospective study T Jin 1, H Lin 2,3, HX Lin 2,3, XY Cai 2,3, HZ Wang 2,3, WH Hu 2,3, LB Guo 4, JZ Zhao 5 * Abstract

More information

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to

More information

Surgery in Head and neck cancers.principles. Dr Diptendra K Sarkar MS,DNB,FRCS Consultant surgeon,ipgmer

Surgery in Head and neck cancers.principles. Dr Diptendra K Sarkar MS,DNB,FRCS Consultant surgeon,ipgmer Surgery in Head and neck cancers.principles Dr Diptendra K Sarkar MS,DNB,FRCS Consultant surgeon,ipgmer Email:diptendrasarkar@yahoo.co.in HNC : common inclusives Challenges Anatomical preservation R0 Surgical

More information